Artykuły w czasopismach na temat „Lin, Li-Chin”

Four new genera and 11 new species of Hahniidae Bertkau, 1878 are described. The new genera are Goblinia Lin & Li, gen. nov., with the type species G. tiane Lin & Li, sp. nov. (♂♀) from Guangxi, China; Myahnia Lin & Li, gen. nov., with the type species M. kanpetlet Lin & Li, sp. nov. (♂♀) from Chin, Myanmar; Troglohnia Lin & Li, gen. nov., with the type species Tr. qiubei Lin & Li, sp. nov. (♂♀) from Yunnan, China and Typhlohnia Lin & Li, gen. nov., with the type species Ty. rongshui Lin & Li, sp. nov. (♂♀) from Guangxi, China. Seven additional new species are described: Tr. dafang Lin & Li, sp. nov. (♂♀) from Guizhou, China; Tr. shidian Lin & Li, sp. nov. (♀) from Yunnan, China; Tr. wuding Lin & Li, sp. nov. (♂♀) from Yunnan, China; Ty. banlaksao Lin & Li, sp. nov. (♀) from Bolikhamxay, Laos; Ty. kaiyang Lin & Li, sp. nov. (♀) from Guizhou, China; Ty. sondoong Lin & Li, sp. nov. (♂♀) from Quang Binh, Vietnam and Ty. suiyang Lin & Li, sp. nov. (♀) from Guizhou, China.

The isolated scattering number is a parameter that measures the vulnerability of networks. This measure is bounded by formulas depending on the independence number. We present new bounds on the isolated scattering number that can be calculated in polynomial time. References Z. Chen, M. Dehmer, F. Emmert-Streib, and Y. Shi. Modern and interdisciplinary problems in network science: A translational research perspective. CRC Press, 2018. doi: 10.1201/9781351237307 P. Erdős and T. Gallai. On the minimal number of vertices representing the edges of a graph. Magyar Tud. Akad. Mat. Kutató Int. Közl. 6 (1961), pp. 181–203. url: http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.210.7468 J. Harant and I. Schiermeyer. On the independence number of a graph in terms of order and size. Discrete Math. 232.1–3 (2001), pp. 131–138. doi: 10.1016/S0012-365X(00)00298-3 E. Korach, T. Nguyen, and B. Peis. Subgraph characterization of red/blue-split graph and Kőnig Egerváry graphs. Proceedings of the Seventeenth Annual ACM-SIAM Symposium on Discrete Algorithms. ACM, New York, 2006, pp. 842–850. doi: 10.1145/1109557.1109650 F. Li, Q. Ye, and Y. Sun. Proceedings of the 2016 Joint Conference of ANZIAM and Zhejiang Provincial Applied Mathematics Association, ANZPAMS-2016. Ed. by P. Broadbridge, M. Nelson, D. Wang, and A. J. Roberts. Vol. 58. ANZIAM J. 2017, E81–E97. doi: 10.21914/anziamj.v58i0.10993 F. Li, Q. Ye, and X. Zhang. Isolated scattering number of split graphs and graph products. ANZIAM J. 58.3-4 (2017), pp. 350–358. doi: 10.1017/S1446181117000062 E. R. Scheinerman and D. H. Ullman. Fractional graph theory. Dover Publications, 2011. url: https://www.ams.jhu.edu/ers/wp-content/uploads/2015/12/fgt.pdf S. Y. Wang, Y. X. Yang, S. W. Lin, J. Li, and Z. M. Hu. The isolated scattering number of graphs. Acta Math. Sinica (Chin. Ser.) 54.5 (2011), pp. 861–874. url: http://www.actamath.com/EN/abstract/abstract21097.shtml M. Xiao and H. Nagamochi. Exact algorithms for maximum independent set. Inform. and Comput. 255, Part 1 (2017), pp. 126–146. doi: 10.1016/j.ic.2017.06.001

Abstract Ferroptosis is an iron-dependent oxidative cell death with accumulation of lipid peroxidation and abnormal morphology of mitochondria. Although previous studies have shown that ferroptosis inducers have therapeutic potentials in several treatment-naive and drug-resistant cancer types, lacking systematic analysis of the ferroptosis sensitivity in different cancer types makes it difficult to know which cancer type is suitable for clinical usage and critical regulator determining the ferroptosis sensitivity during cancer progression is still not clear. In this study, colon cancer was identified as one of the ferroptosis-insensitive cancer types by dry and wet bench analyses. Importantly, our large-scale analysis also showed that NUDT16L1 was a novel ferroptosis repressor and overexpressed in colon cancer clinical specimens. Similar findings are also observed in the chemical-induced and genetic mouse models of colon cancer. Furthermore, NUDT16L1 loss-of-function and gain-of-function cell models and its conditional knock-in and knock-out mouse models are used to prove its crucial role in the development of colon cancer. In addition, loss of NUDT16L1 induced several key ferroptosis characteristics and impairment of mitochondrial functions while its restoration attenuated those phenomena in colon cancer cells. Mechanistically, our RNA-Seq and RIP-Seq analyses shown that NUDT16L1 directly interacted and positively regulated several crucial negative regulators of ferroptosis. More interestingly, loss of NUDT16L1 not only restores the sensitivity of ferroptosis inducer but also impairs the function of mitochondria. Finally, a specific NUDT16L1 inhibitor was shown to not only repress colon cancer growth in vitro and in vivo but also induce the ferroptosis in colon cancer. In conclusion, this is the first study to demonstrate that overexpression of NUDT16L1 promotes colon cancer progression by inhibition of ferroptosis and maintenance proper function of mitochondria. Furthermore, specific NUDT16L1 inhibitor might be a promising therapeutic strategy for colon cancer patient in the future. Citation Format: Yi-Syuan Lin, Ya-Chuan Tsai, Chia-Jung Li, Tzu-Tang Wei, Ya-Na Wu, Shang-Rung Wu, Shin-Chin Lin, Shaw-Jenq Tsai, Shih-Chieh Lin. NUDT16L1 promotes colon cancer progression via inhibition of ferroptosis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1372.

Electrolytes in Li-ion batteries play a significant role as they influence different aspects directly related to the battery performance, such as safety, voltage window, electrochemical stability, and the formation of solid-electrolyte interphase (SEI). Conventionally, these electrolytes are composed of a lithium salt dissolved in an organic solvent such as ethylene carbonate and propylene carbonate. Regarding safety, these organic electrolytes can be replaced by room-temperature ionic liquids (RTILs), which present lower vapor pressure and non-flammability.1 Moreover, adding polymer to these liquid electrolytes to form polymer gel electrolytes has proven to be a good strategy to avoid dendritic growth and increase electrolyte stability.2 The properties of RTIL electrolytes containing Li salts have been studied in the last decade. Still, the scope has been limited primarily to simple RTILs consisting of one cationic and one anionic species. Inspired by the success of high-entropy alloys (HEAs) for forming stable solid solutions with excellent mechanical properties,3 the concept of high-entropy materials has been recently transferred to electrolytes, where the effect of mixing multiple Li salts is explored.4 However, the number of compositional combinations increases rapidly when multiple salts, cationic and anionic species are introduced, and the explorable compositional space increases even more when polymers are added to the mixture. Automating the electrolyte preparation and characterization can be the key feature to allow the exploration of all the possible electrolyte combinations. In this work, we explain the first preliminary results obtained from an autonomous preparation and characterization of high-entropy electrolytes composed of a mixture of two different lithium salts in ionic liquids consisting of multiple anionic and cationic species. In addition, the adaptation of the autonomous system of preparation and characterization of liquid electrolytes to polymer gel electrolytes is also proposed and explained. References. (1) Niu, H.; Wang, L.; Guan, P.; Zhang, N.; Yan, C.; Ding, M.; Guo, X.; Huang, T.; Hu, X. Recent Advances in Application of Ionic Liquids in Electrolyte of Lithium Ion Batteries. J. Energy Storage 2021, 40, 102659. https://doi.org/10.1016/j.est.2021.102659. (2) Chen, J.; Wu, J.; Wang, X.; Zhou, A.; Yang, Z. Research Progress and Application Prospect of Solid-State Electrolytes in Commercial Lithium-Ion Power Batteries. Energy Storage Mater. 2021, 35, 70–87. https://doi.org/10.1016/j.ensm.2020.11.017. (3) Yeh, J.-W.; Chen, S.-K.; Lin, S.-J.; Gan, J.-Y.; Chin, T.-S.; Shun, T.-T.; Tsau, C.-H.; Chang, S.-Y. Nanostructured High-Entropy Alloys with Multiple Principal Elements: Novel Alloy Design Concepts and Outcomes. Adv. Eng. Mater. 2004, 6 (5), 299–303. https://doi.org/10.1002/adem.200300567. (4) Wang, Q.; Zhao, C.; Wang, J.; Yao, Z.; Wang, S.; Kumar, S. G. H.; Ganapathy, S.; Eustace, S.; Bai, X.; Li, B.; Wagemaker, M. High Entropy Liquid Electrolytes for Lithium Batteries. Nat. Commun. 2023, 14 (1), 440. https://doi.org/10.1038/s41467-023-36075-1.

Abstract It is reported that long-term use of estrogen could increase the risk of ovarian cancer. However, the role of estrogen in immunoevasion is not fully explored. We have previously demonstrated that estrogen-mediated upregulation of E2F6, and, c-Kit, by epigenetic silencing of miR-193a, and a competing endogenous (ceRNA) mechanism. In this study, we found that PBX1, a transcriptional activator of the immunosuppressive cytokine, IL-10, is also a target of miR-193a. Importantly, overexpression of the E2F6 3’UTR upregulates both E2F6 and, PBX1, as well as IL10 in ovarian cancer cell lines, suggesting that ceRNA mechanism exists between E2F6 and PBX1. These phenomena are further supported by our stochastic simulation of the estrogen-mediated E2F6 ceRNA network on the distribution of E2F6 and PBX1 mRNA in cancer cells, which is consistent with the TCGA ovarian cancer RNA-Seq dataset. Importantly, monocyte-derived dendritic cell activation of T-cell function was inhibited by pretreatment of conditioned media derived from ovarian cancer cells overexpressing E2F6 3’UTR; such inhibition was rescueable by an anti-IL-10 antibody. Clinically, IL10 level was higher in ovarian cancer patients with higher E2F6 and PBX1, and in ovarian cancer cell lines overexpressed with E2F6 3’UTR. Taken together, these results showed that E2F6 could suppress anti-tumor immune response of dendritic cell, E2F6 ceRNA network. Epigenetic intervention in restoring the expression of miR-193a may be able to enhance anti-tumor immune response against ovarian cancer. Citation Format: Michael W.Y. Chan, Yin-Chen Chen, Ching-Wen Lin, Frank Cheng, Ching-Cher Sanders Yan, Chao-Ping Hsu, Yu-Min Chuang, Jie-Ting Low, Xiaojing Ma, Yao-Ting Huang, Chia-Bin Chang, Chin Li, Hung-Cheng Lai, Shu-Fen Wu, Shih-Hsun Hung, Je-Chiang Tsai. A E2F6 ceRNA network suppresses dendritic cell function, via PBX1/IL-10 signaling, in ovarian cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 97.

Abstract Twenty-one gliomas in patients aged 0-21 years were evaluated for drug sensitivity by ex vivo expanded circulating tumor cells (CTC). The results were correlated with clinical outcomes. Venous blood samples were obtained prior to drug treatment. Peripheral blood mononuclear cells were processed in a 3D cell culture system (EVA Select™, Cancer Free Biotech Ltd., Taipei, Taiwan) and cultured for 3 weeks. Expanded CTCs were successfully cultured into organoids from 18 out of 21 patients and were analyzed for ATP abundance. Staining with CD45, a marker for blood cells, and pancytokeratin, a marker for keratinocytes, was performed on the cultured cells. Staining of GFAP, a marker of glioma cells, was performed in a subset of samples. These cells were then tested in cytotoxicity assays in triplicate with a panel of chemotherapeutic and targeted agents at clinically relevant concentrations. The surviving fraction was normalized to a buffer-only control. Based on the percentage of cell viability, the agent was chosen for clinical treatment. Comparing the results among low-grade glioma (LGG; n = 6), diffuse midline glioma (DMG; n = 4), and high-grade glioma (HGG, n = 8; including glioblastoma multiforme [GBM; n = 5]), the mean surviving fraction to temozolomide was similarly high across the three tumor types (LGG vs. DMG vs. HGG = 57.5% vs. 50.6% vs. 49.5%, respectively). 6 of 6 patients in the LGG group showed CTC sensitivity to at least one chemotherapeutic agent tested. The clinical response of patients treated with selected agents was evaluated with the RANO criteria at 6 months after initiation of treatment. Among the 24 agents tested with clinical correlation, the CTC surviving fraction after exposure to the agent was significantly higher in patients who had progressive disease within 6 months (n = 11; 68%) vs. in patients with no progression at 6 months (n = 13; 39%; P = 0.039). Treating CTCs with histone deacetylase inhibitors in vitro resulted in a consistently lower surviving fraction (15.1% ± 12.0%) for DMG and HGG/GBM; however, clinical correlation was not available. The 1 patient with clinical correlation with HGG had a 34.9% surviving fraction to a Tyrosine kinase inhibitor (TKI) in vitro and showed a 42.9% shrinkage at 6 months after treatment with the TKI. The expansion of CTCs in patients with relapsed/refractory pediatric gliomas provides the ability to test drug sensitivity of patient-derived organoids. Our data suggest a correlation between the ex vivo drug sensitivity of CTCs and clinical response. Citation Format: Yen-Lin Liu, Yin-Ju Chen, Shu-Huey Chen, Yu-Mei Liao, Wu Shih-Pei, Yi-Hsuan Chen, Wan-Ling Ho, Liang-Yi Juo, Chia-Yau Chang, Jinn-Li Wang, Min-Yu Su, Pei-Chin Lin, Shih-Chung Wang, James S. Miser, Tai-Tong Wong, Yuan-Hung Wu, Peng Yuan Wang, Thierry Burnouf, Jeng-Fong Chiou, Long-Sheng Lu. Application of in vitro drug screening of circulating tumor cells in pediatric glioma therapy. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6723.

Abstract Cancer cells need metabolic adaptations to survive in hostile environment such as low nutrient and drug treatment conditions. DLBCLs (Diffuse large B cell lymphoma) originate from a metabolic competitive/challenging environment of germinal center (GC) when B cells undergo positive selections against antigens. However, it is largely unknown whether and how metabolic flexibility (the ability to use different nutrients) and plasticity (the ability to process the same nutrient differently) contribute to DLBCLs. Our previous study identified that SIRT3, the only mitochondrial protein deacetylase, is critical to survival and proliferation of DLBCLs by promoting glutaminolysis. Our mitochondrial localized SIRT3 inhibitor, YC8-02, has pan-toxicity to all DLBCL cells tested regardless of different subtypes with somatic mutations. Here, we observed glucose as an alternative nutrient source to compensate in the TCA cycle in SIRT3 deficient cells. DLBCLs exhibited resistance to SIRT3 inhibition in high glucose condition, while SIRT3 inhibited DLBCLs highly depend on glucose metabolism. The combination of YC8-02 with glucose metabolism inhibitors induces synergistic killing to DLBCLs. As glucose is the main carbon source of cells, it is unknown how DLBCLs manage the flexibility of using glucose for different purposes. Using in vivo metabolic imaging (MALDI), we observed that, in contrast to normal GC B cells, lymphomas specifically use the glucose for de novo nucleotide synthesis. SIRT3 inhibition decreased nucleotide levels in DLBCL cells in vitro and in vivo. The metabolic flux tracing showed that DLBCL cells requires SIRT3 activity to activate a glucose/serine/one-carbon metabolism pathway for de novo nucleotide biosynthesis, and Inhibition of SIRT3 decreased the glucose and serine being used for nucleotides in DLBCLs. Serine as another potent source for nucleotides can rescue DLBCLs from SIRT3 inhibition. Furthermore, we validated that overexpression of enzymes, like MTHFD2, in one carbon metabolism pathway can rescue the proliferation in SIRT3 deficient cells. High nucleotides levels in medium also help DLBCLs survival in YC8-02 treatments. To overcome the metabolic flexibility on environmental nucleotides, we used inhibitors of nucleoside transporters (ENT1/2), dipyridamole and draflazine, which can synergize with YC8-02 to kill DLBCLs in vitro and eradicate systemic lymphomas in vivo. In summary, our results illustrate that DLBCLs with active SIRT3 exhibit metabolic plasticity by repurposing glucose to nucleotide biosynthesis, while lymphoma cells can also reply on metabolic flexibility to manage nutrient usage and gain extracellular nucleotides for survival under SIRT3 inhibition. Our combination treatment SIRT3 and ENT inhibitors can be a promising therapy for DLBCLs by restraining their metabolic plasticity and flexibility. Citation Format: Meng Li, Noel R Park, Chris Chin, Coraline Mlynarczyk, Hening Lin, Shawn Davidson, Ari M Melnick. Targeting metabolic plasticity and flexibility via SIRT3 inhibition to restrain nucleotides availability in DLBCLs [abstract]. In: Proceedings of the Fourth AACR International Meeting on Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application; 2024 Jun 19-22; Philadelphia, PA. Philadelphia (PA): AACR; Blood Cancer Discov 2024;5(3_Suppl):Abstract nr PO-034.

Introdução: A COVID-19 tornou-se uma emergência de saúde pública no ano de 2020, sendo caracterizada como pandemia no mês de março. Os idosos compõem o grupo de risco dessa doença. Objetivo: Avaliar os efeitos da pandemia de COVID-19 sobre os idosos. Material e Método: A busca pelos artigos foi realizada através da plataforma Pubmed, com a inclusão de 17 estudos. Resultados: Os resultados ressaltaram a prevalência da doença entre a população idosa, e evidenciaram que esse grupo apresenta sintomas atípicos e com duração ligeiramente mais longa desde o início da sintomatologia até a sua admissão, tornando-se mais difícil a identificação da infecção de forma precoce. As manifestações clínicas mais relatadas foram: febre, tosse, produção de escarro, diarreia, fadiga, pneumonia e lesão cardíaca aguda. Também se observa que comorbidades, como hipertensão e doença pulmonar obstrutiva crônica, levam a uma disfunção cardíaca e pulmonar devido a mudanças fisiológicas e anatômicas dos pulmões, agravando o quadro clínico dos pacientes. Os exames de imagem se mostraram grandes aliados ao diagnóstico das alterações pulmonares decorrentes da infecção, além da realização do exame RT-PCR. Conclusão: Os idosos compõem o grupo de risco da COVID-19, sendo indivíduos com comorbidades os mais susceptíveis à agravamentos clínicos. Há necessidades em seguir as recomendações da OMS por não haver um tratamento específico destinado a essa patologia. Descritores: Infecções por Coronavírus; Idoso; Diagnóstico Clínico. Referências World Health Organization [homepage internet]. Pandemia de doença por coronavirus (COVID-19) [acesso em 19 nov 2020]. Disponível em: http: https://www.who.int/emergencies/diseases/novel-coronavirus-2019?gclid=CjwKCAiAzN j9BRBDEiwAPsL0d-MtvP29HNfG_fKThMRyfZF5ZAhTrrwKXEDh74AOZlY7ddRjJ_su0 hoCK3EQAvD_BwE. Organização Pan-Americana de Saúde [homepage na internet]. Folha informativa COVID-19 - Escritório da OPAS e da OMS no Brasil [acesso em: 19 nov. 2020]. Disponível em: https://www.paho.org/pt/covid19. Ministério da Saúde [homepage na internet]. Painel Coronavirus Brasil [acesso em: 19 nov. 2020]. Disponível em: http:https://covid.saude.gov.br/. Liu K, Zhang W, Yang Y, Zhang J, Li Y, Chen Y. Respiratory rehabilitation in elderly patients with COVID-19: A randomized controlled study. Complement The Clin Pract. 2020:101166. Lee JY, Kim HA, Huh K, Hyun M, Rhee J-Y, Jang S, et al. Risk Factors for Mortality and Respiratory Support in Elderly Patients Hospitalized with COVID-19 in Korea. J Korean Med Sci. 2020;35(23) Nikpouraghdam M, Farahani AJ, Alishiri G, Heydari S, Ebrahimnia M, Samadinia H, et al. Epidemiological characteristics of coronavirus disease 2019 (COVID-19) patients in IRAN: A single center study. J Clin Virol. 2020; 127:104378. Zheng Y, Xu H, Yang M, Zeng Y, Chen H, Liu R, et al. Epidemiological characteristics and clinical features of 32 critical and 67 noncritical cases of COVID-19 in Chengdu. J Clin Virol. 2020;127:104366. Porcheddu R, Serra C, Kelvin D, Kelvin N, Rubino S. Similarity in case fatality rates (CFR) of COVID-19/SARS-COV-2 in Italy and China. J Infect Dev Ctries. 2020;14(02):125-8. Buckner FS, McCulloch DJ, Atluri V, Blain M, McGuffin SA, Nalla AK, et al. Clinical Features and Outcomes of 105 Hospitalized patients with COVID-19 in Seattle, Washington. Clin Infect Dis. 2020;71(16):2167-73. Liu K, Fang Y-Y, Deng Y, Liu W, Wang M-F, Ma J-P, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J. 2020;133(9):1025-31. Zhao M, Wang M, Zhang J, Gu J, Zhang P, Xu Y, et al. Comparison of clinical characteristics and outcomes of patients with coronavirus disease 2019 at different ages. Aging (Albany NY). 2020;12(11):10070. Wang L, He W, Yu X, Hu D, Bao M, Liu H, et al. Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up. J Infect. 2020;80(6):639-45. Guo T, Shen Q, Guo W, He W, Li J, Zhang Y, et al. Clinical Characteristics of Elderly Patients with COVID-19 in Hunan Province, China: A Multicenter, Retrospective Study. Gerontol. 2020:1-9. Ward CF, Figiel GS, McDonald WM. Altered Mental Status as a Novel Initial Clinical Presentation for COVID-19 Infection in the Am J Geriatr Psychiatry. 2020;28(8):808-11. Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients. J Infect. 2020;80(6):e-14-8. Li T, Zhang Y, Gong C, Wang J, Liu B, Shi L, et al. Prevalence of malnutrition and analysis of related factors in elderly patients with COVID-19 in Wuhan, China. Eur J Clin Nutr. 2020:1-5. Niu S, Tian S, Lou J, Kang X, Zhang L, Lian H, et al. Clinical characteristics of older patients infected with COVID-19: A descriptive study. Arch Gerontol Geriatr. 2020;89:104058. Fatyga E, Dzięgielewska-Gęsiak S, Wierzgoń A, Stołtny D, Muc-Wierzgoń M. The coronavirus disease 2019 pandemic: telemedicine in elderly patients with type 2 diabetes. Pol Arch int Med. 2020;130(5):452-54. Li P, Chen L, Liu Z, Pan J, Zhou D, Wang H, et al. Clinical Features and Short-term Outcomes of Elderly Patients With COVID-19. Int J Infect Dis. 2020;97:245-50. Kumar A, Kubota Y, Chernov M, Kasuya H. Potential Role of Zinc Supplementation in Prophylaxis and Treatment of COVID-19. Med Hypotheses. 2020;144:109848.

Objective: To assess the relationship between Helicobacter pylori (Hp) infection and primary open-angle glaucoma (POAG); and meantime, to explore the possible mechanism of POAG induced by Hp. Methods: 30 consecutive POAG patients, 30 primary angle-closure glaucoma (PACG) and cataract patients were recruited and divided into three groups according to different diseases. The sera and aqueous humor samples were collected and used to detect Hp-specific IgG antibody (Hp-Ab) with dot immunogold filtration assay (DIGFA). 14C-urea breath test (14C-UBT) was carried out to detect Hp infection of all participants. Results: The Hp-Ab positive rate respectively was 76.7% (23/30) and 66.7% in sera samples and aqueous humor samples for POAG group, which was significantly higher than the corresponding data of the other two groups (all P<0.05). In 14C-UBT, the Hp-Ab positive rate was 63.3% in POAG group and it was close to that of serological result detected by DIGFA (P>0.05). There were little numbers of positive ANA and ENA in the three groups and no meaning to make statistically analysis. Conclusions: There is positive association between Hp infection and POAG, and the autoimmune is suggested as one of the key mechanisms in our opinions. Introduction Glaucoma is one of the commonest causes for blindness in the world. Generally, glaucoma is divided into primary open-angle glaucoma (POAG) and primary angle-closure glaucoma (PACG).1 As a leading causes for blindness, the study of POAG causes more and more attention.2,3To our understand, POAG is a chronic optic neuropathy characterized by atrophy and increased cupping of optic disk. To date, many aspects of its pathogenesis remain unknown but some significant risk factors are advanced age, African origin, familial history of glaucoma and elevated intraocular pressure.4,5 Helicobacter pylori (Hp) is a Gram-negative and microaerophilic bacterium which plays an important role in the development of various upper gastrointestinal diseases. With the development of studies, some researchers reported that Hp was also associated with some extragastric diseases, such as ischemic heart disease,6 iron-deficient anemia,7 diabetes mellitus,8 and so on. In 2001, Kountouras et al9 established a higher prevalence of Hp infection in the sera of patients with POAG in a Greek population, and suggested a possible causal link between Hp and glaucoma. Subsequently, this finding was evidenced by some scholars in their own studies.10 But the significance of such an association remains uncertain because of the conflicting findings reported by various studies.11-13 Aiming to such a discrepancy, further studies are necessary.14 In this study, we just do detect Hp-specific IgG antibodies (Hp-Ab) in the sera and aqueous humor of patients with different ocular diseases, including POAG, PACG and cataract, and attempt to further determine the relationship between Hp infection and POAG and to analyze the possible mechanism of POAG induced by Hp. Abbreviations ANA, antinuclear antibody; ENA, Extractable nuclear antigen; DIGFA, dot immunogold filtration assay; Hp, Helicobacter pylori; Hp-Ab, Hp-specific IgG antibodies; PACG, primary angle-closure glaucoma; POAG, primary open-angle glaucoma; 14C-UBT: 14C-urea breath test. Subjectsand methods Subjects 30 consecutive POAG patients were enrolled with the average age of 68±7.3 y (ranged from 47 to 78 y). The ratio of the male and the female was 11: 19. Meantime, 30 PACG patients and 30 cataract patients were also recruited, and who were matched by age and sex with the POAG patients. According to different diseases, the participants were divided into POAG, PACG and cataract groups, respectively. All of them were excluded from tumor, immunodeficiency, autoimmune and infectious diseases in clinic, and also had no antibiotics and other medicines related to immunopotentiator or immunosuppressive agents in the six months before the experiment. Written informed consents were obtained from all the participants. The study was approved by the local ethics committee. Hp-Ab detection of sera samples 2 ml venous blood was collected from each of the participants. The serum was obtained after centrifugation and used to detect Hp-Ab with dot immunogold filtration assay (DIGFA) according to the manufacturer’s instruction of the reagent kit (MP Biomedicals Asia-Pacific Pte. Ltd., Singapore). Hp-Ab detection of aqueous humor samples About 50 μl aqueous humor sample was aspirated at the beginning of glaucoma surgery from the each of the patients in the three groups, respectively. Hp-Ab was assayed with DIGFA as same as the detection process of venous blood samples. Detection of Hp infection with 14C-urea breath test Referring to Tang’s report,1514C-urea breath test (14C-UBT) was carried out in POAG group with Hp detection instrument-YH04 (Yanghe Medical Equipment Co. Ltd., China). Sera auto-antibodies detection Serum antinuclear antibody (ANA) was detected with the indirect immunofluorescence assay by a commercialized ANA kit. Extractable nuclear antigen (ENA) was assayed with line immunoassay. All reagents were bought from Jiangsu HOB Biotech Group, China. Statistic analysis Using T-test and Chi-square test, all analyses were performed with SPSS 13.0 software. P value less than 0.05 were considered significant. Results 3.1 Hp infection detection in sera and aqueous humor Of the sera samples, there were 23 cases exhibited Hp-Ab-positive in POAG group, and the positive rate was 76.7% which was significantly higher than those of PACG and cataract group (43.3% and 36.6% respectively). In the aqueous humor samples, there were 18 patients with positive Hp-Ab in POAG group, and the positive rate was 66.7%. Compared to each data of the other two groups, the difference was statistically significant (Table 1). In POAG group, the mean positive rate of sera samples was similar to that of aqueous humor and no difference existed between them (P = 0.287). Table 1. The serum and aqueous humor qualitative test results of the patients with glaucoma Hp infection detection with 14C-UBTAH: aqueous humor; a: POAG group vs cataract group; b: POAG group vs PACG group; c: PACG group vs cataract group. In 14C-UBT, there were 19 patients with Hp-Ab-positive, and the positive rate was 63.3%. Compared to the data detected with DIGFA, the difference was not significant (Table 2). Table 2. Comparison of DIGFA and 14C-UBT for diagnosis of Hp infection in POAG group ANA and ENA detection* represents comparison of the positive rate detected with the two methods. There were 4, 2 and 1 patients with ANA-positive in POAG, PACG and cataract group, respectively. The positive ENA in POAG group were SSA, SSB and Ro-52, and the corresponding numbers were 2, 2 and 1. Only Ro-52 showedpositive in PACG group while there was no positive ENA in cataract group (Table 3). Table 3. The results for sera ANA, ENA of the patients of each group Discussion In Greece, a very active research group led by J. Kountouras published several original contributions as well as the reviews concerning the connection between Hp infection and POAG.14,16 In other counties, there were also several papers containing the similar arguments issued, such as India,17 Turkey,18 Korea19 and so on. In China, Hong et al20 detected Hp infection and POAG through 13C-UBT, and also found the positive correlation between them. Since then, there was no relative article issued by Chinese could be found in PubMed and other well-known scientific database. In this study, referring to other researchers’ reports, we designed and carried out the experiments. In the results, we found that the positive rate of sera Hp-Ab was high to 76.7% in POAG patients, which was significantly higher than those of the other two groups. This finding was close to the data of the previous reports2,21 and further verified that there was a positive relation between Hp infection and POAG. In the present study, we also assayed Hp infection with 14C-UBT. Encouragingly, the positive rate of Hp infection was 63.3%, which was very close to 76.7% detected with DIGFA. This result further indicated the existence of the relation between Hp infection and POAG. However, Bagnis et al22 thought that the studies based on Hp serological assessment might be misleading, since serum antibodies were not the sensitive markers of active Hp infection; while 13C-UBT could clarify the actual prevalence of POAG among patients infected by Hp. In fact, there were still deficiencies for 13C- or 14C -UBT, because it was more suitable for the detection of gastrointestinal Hp infection, and to an extent, there were false-negatives in the test.23 This probably was the just reason for what the positive rate in DIGFA was little higher than that in 14C-UBT in this study. As to the cresyl fast violet staining on the histology preparations of tissue samples of trabeculum and iris introduced by Zavos et al,24 although it could provide the direct and strong evidence for Hp infection in the pathophysiology of POAG, the difficult harvest of the sample limited its application. Therefore, in our opinions, the serological assay is suitable to detect Hp infectionand used to assess the relationship between Hp prevalence and POAG. Except for detecting sera Hp-Ab, we also detected Hp-Ab in the aqueous humor collected from the majority of participants. As the results shown, the positive rate of the POAG group was statistically higher than each of the other groups, respectively. This result was consistent with that of the serological assessment and again showed the positive relation between Hp infection and POAG. However, in another similar study, Deshpande et al17 also found a statistically significant difference between the POAG patients and the controls in the concentration of serum Hp-Ab, but they did not find any significant correlations between the Hp concentrations of the aqueous humor of the different patient groups. This disagreement probably associated with the damage degree of blood-brain barrier (BBB), because the sera Hp-Ab could reach the trabeculum and iris under the condition of the BBB disruption.25 According to the results of the present study, we supported the hypothesis related to POAG onset that Hp-Ab in circulation might get through the blood-aqueous humor barrier, further condensed in aqueous humor and finally induced or aggravated glaucomatous damage.2 As to the occurrence of POAG, we thought another autoimmune mechanism was most probable and should not be ignored: Hp infection initiated autoimmune response because of the common genetic components shared in Hp and human nerve tissue; and then, cell destruction which mediated by apoptosis direct caused glaucoma.26 Just based on the theory, we designed and detected sera ANA and ENA of the POAG patients and the control participants, and hoped to find any evidences related to autoimmune. As a result, we found that the positive rate of every group was rather low and there was no difference between them. However, this seronegative result can’t deny the hypothesis of autoimmune mechanism in POAG; and the auto-antibodies specific to eyes, such as trabeculum and iris, were suggested to be detected in future study in our opinions. Conclusion The positive association between Hp infection and POAG not only using serum sample but also aqueous humor sample is found in this study. And further, through the experimental data, it is suggested that the autoimmune induced by Hp infection probably is the key mechanism for POAG onset, and Hp detection should be taken as a routinized index applied to the prevention and therapy of POAG in clinic. However, we can not sufficiently investigate the possible mechanism of POAG relates to Hp infection. Is it true that Hp infection only relative to POAG but not a causative factor for POAG?18 What are the initial mechanisms of Hp in POAG if the pathogen takes part in the onset of the disease? Such questions will be the study topics to the medical researchers worldwide in future. Funding This work is supported by the Research Fund for Lin He’s Academician Workstation of New Medicine and Clinical Translation in Jining Medical University(JYHL2018FMS08), and the Project of scientific research support fund for teachers of Jining Medical University (JYFC2018FKJ023). Conflicts of interest There is no any conflict of interest between all of the authors. References: Chan H. H.; Ng Y.F.; Chu P. H. Clin Exp Optom. 2011, 94, 247. Kountouras J.; Mylopoulos N.; Konstas A. G.; Zavos C.; Chatzopoulos D.; Boukla A. Graefe’s Arch Clin Exp Ophthalmo. 2003, l241, 884. Kim E. C.; Park S. H.; Kim M. S. A. J. Pharmacol. Ther. 2010, 26, 563. Cantor L.; Fechtner R. D.; Michael A. J. San Francisco: Foundation of American Academy of Ophthalmology. 2005, 8. Bron A.; Chaine G.; Villain M.; Colin J.; Nordmann J. P.; Renard, J.P.; et al. Fr. Ophtalmol. 2008, 31, 435. Suzuki H.; Franceschi F.; Nishizawa T.; Gasbarini A. Helicobacter. 2011, 16, 65. Xia W.; Zhang X.; Wang J.; Sun C.; Wu L. Br. J. Nutr. 2011, 18, 1. Schimke K.; Chubb S. A.; Davis W. A.; Davis T. M. Atherosclerosis. 2010, 212, 321. Kountouras J.; Mylopoulos N.; Boura P.; Bessas C.; Chatzopoulos D.; Venizelos J.; et al. Opthalmology. 2001, 108, 599. Zaidi M.; Jilani A.; Gupta Y.; Umair S.; Gupta M. Nep. J. Oph. 2009, 1, 129. Galloway P. H.; Warner S. J.; Morshed M. G.; Mikelberg F. S. Ophthalmology. 2003, 110, 922. Abdollahi A.; Zarei R.; Zare M.; Kazemi A.Iran J. Opththalmol. 2005, 18, 15. Kurtz S.; Regenbogen M.; Goldiner I.; Horowitz N.; Moshkowitz M. Glaucoma. 2008, 17, 223. Tsolakin F.; Gogaki E.; Sakkias F.; Skatharoudi C.; Lopatatzidi C.; Tsoulopoulos V.; et al. Ophthalmol. 2012, 6, 45. Tang H. R.; Fan Y. J.; Liu S. Sichuan Da Xue Xue Bao Yi Xue Bao. 2014, 45, 823. Zavous, C.; Kountouras, J. Ophthalmol. 2012, 6, 243. Deshpande N.; Lalitha P.; Krishna das S. R.; Jethani J.; Pillai R. M.; Robin A.; et al. Glaucoma. 2008, 17, 605. Öztürk F.; Kurt E.; Inan U. U.; Erm S. S.; Çetinkaya Z.; Altýndi M. African J. Res. 2009, 3, 560. Kim J. M.; Kim S. H.; Park K. H.; Han S. Y.; Shim H. S. Invest Ophthalmol. Vis. Sci. 2011, 52, 665. Hong Y.; Zhang C. H.; Duan L.; Wang E. Asian J. Ophthalmol. 2007, 9, 205. Samarai V.; Shrif N.; Nateghi S. Glob. J. Health Sci. 2014, 6, 13. Bagnis A.; Izzotti A.; Saccàn S. C. Diagestive and Liver Disease. 2012, 44, 962. Gao F.; Li W. X. Chin. J. Gastroenterol. 2015, 20, 151. Zavos C.; Kountouras J.; Sakkias G.; Venizelos L.; Deretzi G.; Arapoglou, S. Res. 2012, 47, 150. Kountouras J.Br. J. 2009, 93, 1413. Kountouras J.; Gavalas E.; Zavos C.; Stergiopoulos C.; Chatzopoulos D.; Kapetanakis N.; et al. . Hypotheses. 2007, 68, 378.

The field of graphic narratives linked to the Chinese cultural sphere is developing significantly in the francophone world. This movement is due to the translation of Chinese creators into French, francophone creators travelling to China, sinophone creators deciding to live in a francophone country or francophone creators of Chinese origins. This article is an introduction to this diverse and dynamic phenomenon, through a presentation of some trends in translation, then in graphic travelogues in China and finally the specific contributions of some creators. Among them, Chen Jiang Hong shares with his francophone readership Chinese pictural arts as much as his memories of the Cultural Revolution. Li-Chin Lin, a Taiwanese creator living in France, exposes in French the challenges of a personal itinerary constantly facing contradictory political ideologies. Finally, Kei Lam opens a path for francophone creations of artists with a sinophone background where the challenges of multiculturality stimulate a joyful reinvention of both self-identity and social togetherness. RÉSUMÉ Jean-Baptiste Bernard trace, dans cet article, le passage des cultures aux identités plurielles révélé dans des romans graphiques et des bandes dessinées sino-francophones. Il prend note du fait que le champ de ces ouvrages liés au monde chinois connaît un important développement dans le monde francophone. Auteurs chinois traduits en français, auteurs francophones voyageant en Chine, auteurs de pays sinophones décidant de vivre dans un pays francophone ou auteurs francophones d’origine chinoise en sont autant d’acteurs. Il propose une introduction à ce phénomène dynamique et transculturel à travers une présentation des tendances éditoriales en général, puis de certains auteurs en particulier. À titre d’exemple, Chen Jiang Hong, auteur et illustrateur d’albums pour la jeunesse, transmet aussi bien la culture traditionnelle de la Chine que l’histoire qui l’a mené à vivre en France. Li-Chin Lin, originaire de Taiwan, explore en français les défis du devenir individuel sans cesse confronté aux discours politiques, ceux du Parti communiste et du Kuomintang comme des libéraux européens. Enfin, Kei Lam inaugure une création francophone d’auteurs issus de l’immigration chinoise où les défis de la multiculturalité stimulent une réinvention heureuse du soi et du vivre-ensemble. English title: From Intercultural Relations to Plural Identities: Sino-Francophone Graphic Narratives

Extensive lip injuries reconstructions require a strategy of treatment. First, the strategy can follow the anatomical references in order to closure the injury reestablishing the lip functions. This article report a reconstruction of an extensive lip injury after a convulsion and a fall in height in a male patient. The lip reconstruction by anatomical reconstruction was effective for immediate structural maintenance and allowed a favorable healing for the second surgical stage.Descriptors: Lip; Wounds and Injuries; Surgery, Oral.ReferencesMatin MB, Dillon J. Lip reconstruction. Oral Maxillofac Surg Clin North Am. 2014;26(3):335-57.Lubek JE, Ord RA. Lip reconstruction. Oral Maxillofac Surg Clin North Am. 2013;25(2):103-14.Cakmak MA, Cinal H, Barin EZ, Sakat MS, Karaduman H, Tan O. Total lower lip. reconstruction with functional gracilis free muscle flap. J Craniofac Surg. 2018;29(3):735-37.Larrabee YC, Moyer JS. Reconstruction of mohs defects of the lips and chin. Facial Plast Surg Clin North Am. 2017;25(3):427-42.Coppit GL, Lin DT, Burkey BB. Current concepts in lip reconstruction. Curr Opin Otolaryngol Head Neck Surg. 2004;12(4):281-87.Daraei P, Calligas JP, Katz E, Etra JW, Sethna AB. Reconstruction of upper lip avulsion after dog bite: case report and review of literature. Am J Otolaryngol. 2014;35(2):219-25.Sanniec KJ, Carboy JA, Thornton JF. Simplifying Lip Reconstruction: An Algorithmic Approach. In Semin Plast Surg. 2018;32(2):69-74.Neligan PC. Strategies in lip reconstruction. Clin Plast Surg. 2009;36(3):477-85.Bai S, Li RW, Xu ZF, Duan WY, Liu FY, Sun CF. Total and near-total lower lip reconstruction: 20 years experience. J Craniomaxillofac Surg. 2015;43(3):367-72.Ogawa R. Surgery for scar revision and reduction: from primary closure to flap surgery. Burns Trauma. 2019;7:7 doi: 10.1186/s41038-019-0144-5.Siqueira EJ, Alvarez GS, Laitano FF, Martins PDE, Oliveira MP. Estratégias em reconstrução do lábio inferior. Rev Bras Cir Plást.2012;27(4):536-41.Estlander JA. Eine methode aus der einen lippe substanzverluste der anderen zu erstzen. Arch Klin Chir. 1872;14:622. Reprinted in English in Plast Reconstr Surg. 1968;42:361.Robotti E, Righi B, Carminati M, Ortelli L, Bonfirraro PP, Devalle L et al. Oral commissure reconstruction with orbicularis oris elastic musculomucosal flaps. J Plast Reconstr Aesthet Surg. 2010;63(3):431-39.Yamauchi M, Yotsuyanagi T, Ezoe K, Saito T, Yokoi K, Urushidate S. Estlander flap combined with an extended upper lip flap technique for large defects of lower lip with oral commissure. J Plast Reconstr Aesthet Surg. 2009;62(8):997-1003.

Цель статьи – определение фазового состава структур пленочных постоянных магнитов со слоями сплава Fe-Cr-Co микронного диапазона толщин, называемого сплавом Kaneko. Знание фазового состава необходимо для разработки физико-технологических подходов создания оптимальных структур на подложках монокристаллического кремния с пленочным постоянным магнитом на основе дисперсионно-твердеющего сплава с вектором намагниченности в плоскости кремниевой подложки.Методом магнетронного напыления на кремниевой подложке были получены трехслойные металлические пленки: слой дисперсионно-твердеющего сплава на основе системы Fe-Cr-Co (толщиной 3600 нм), компенсационный медный слой (3800 нм) и ванадиевый адгезионно-барьерный слой (110 нм). Сформированные на кремниевой подложке многослойные пленки подвергались одноминутному отжигу в высоком вакууме в диапазоне температур 600–650 °С. Методом рентгеновской дифракции выполнен качественный фазовый анализ структур, полученныхмагнетронным напылением и подвергнутых одноступенчатой термической обработке.Определено, что в слое дисперсионно-твердеющего сплава на основе системы Fe-Cr-Co, полученного магнетронным напылением, не образуются окислы основных компонентов и s-фаза, как в процессе получения, так и после высоковакуумного «быстрого» одноминутного отжига в диапазоне температур 600–650 °С. При температуре отжига 630 °С наблюдается максимальная интенсивность рентгеновской линии (110) a-фазы, что свидетельствует о формировании преимущественно a-твердого раствора и является предпосылкой для корректного проведения последующих ступеней отжига для спинодального распада этой фазы. ЛИТЕРАТУРА Kaneko H., Homma M., Nakamura K. New ductile permanent magnet of Fe-Cr-Co system. AJP Conference Proceedings. 1972;5: 1088–1092. DOI: https://doi.org/10.1063/1.2953814 Tsung-Shune Chin, Kou-Her Wang, Cheng-Hsiung Lin. High coercivity Fe-Cr-Co thin fi lms by vacuum evaporation. Japanese Journal of Applied Physics. 1991;30(8): 1652–1695. DOI: https://doi.org/10.1143/jjap.30.1692 Chang H. C., Chang Y. H., Yao S. Y. The magnetic properties and microstructures of Fe-Cr-Co thin fi lms obtained by ion beam sputtering. Materials Science and Engineering B. 1996; 39(2): 87–94. DOI: https://doi.org/10.1016/0921-5107(95)01428-4 Masahiro Kitada, Yoshihisa Kamo, Hideo Tanabe. Magnetoresistive thin-fi lm sensor with permanent magnet biasing film. Journal of Applied Physics. 1985;58(4): 1667–1670. DOI: https://doi.org/10.1063/1.336058 Rastabi R. A., Ghasemi A., Tavoosi M., Ramazani M. Magnetic features of Fe-Cr-Co alloys with tailoring chromium content fabricated by spark plasma sintering. Magnetic Materials. 2017;426(15): 742–752. DOI: https://doi.org/10.1016/j.jmmm.2016.10.132 Zubair Ahmad, Zhongwu Liu, A. ul Haq. Synthesis, magnetic and microstructural properties of Alnico magnets with additives. Journal of Magnetism and Magnetic Materials. 2017;428: 125–131. DOI: https://doi.org/10.1016/j.jmmm.2016.12.023 Jin Y., Zhang W., Kharel P. R., Valloppilly S. R., Skomski R., Sellmyer D. J. Effect of boron doping on nanostructure and magnetism of rapidly quenched Zr2Co11-based alloys. AIP Adv. 2016;6(5): 056002. DOI: https://doi.org/https://doi.org/10.1063/1.4942556 Lin Zhang, Zhaolong Xiang, Xiaodi Li, Engang Wang. Spinodal decomposition in Fe-25Cr-12Co alloys under the infl uence of high magnetic fi eld and the effect of grain boundary. Nanomaterials (Basel). 2018;8(8): 578. DOI: https://doi.org/10.3390/nano8080578 Zayonchkovskiy V., Kyaw A. K., Milyaev, I., Perov N., Prokhorov I., Klimov A., Andreev A. (2019). Thin metal fi lms with dispersion-hardening magnetic layers of Fe–Cr–Co alloy. Kondensirovannye Sredyi Mezhfaznye Granitsy = Condensed Matter and Interphases. 2019;21(4): 505–518. DOI: https://doi.org/10.17308/kcmf.2019.21/2362 Миркин Л. И. Справочник по рентгеноструктурному анализу поликристаллов. М.: Физматгиз; 1961. 863 с. Сайт компании NanoFocus. Режим доступа: https://m.nanofocus.de/en/ Сайт компании ООО “ГЕО-НДТ”. Режим доступа: https://www.geo-ndt.ru/pribor-6855-rentgenoflyorescentnii-analizator-metekspert.htm Справочник по цветным металлам. Режим доступа: https://libmetal.ru/index.htm Сайт «Всё о металлургии». Режим доступа: http://metal-archive.ru/vanadiy/955-mehanicheskiesvoystva-vanadiya.html Громов Д. Г. Мочалов А. И., Сулимин А. Д., Шевяков В. И. Металлизация ультрабольших интегральных схем. М.: БИНОМ; 2012. 277 с. Лякишев Н. П., Банных О. А., Рохлин Л. Л. Диаграммы состояния двойных металлических систем: Справочник в трех томах. М.: Машиностроение; 1997. 872 c. Кекало И. Б., Самарин Б. А. Физическое металловедение прецизионных сплавов. Сплавы с особыми магнитными свойствами. M.: Металлургия; 1989. 496 с. ГОСТ 24897-81. Материалы магнитотвердые деформируемые. Solid magnetic deformed materials. Marks. М.: Издательство стандартов; 1981. 21 с. Bragg W. L. The diffraction of short electromagnetic waves by a crystal. Proceedings of the Cambridge Philosophical Society, 17, 43–57 (1913). Communicated by Professor Sir J. J. Thomson. Read 11 November 1912. In: X-ray and Neutron Diffraction. Elsevier; 1966. p. 19–125. DOI: https://doi.org/10.1016/b978-0-08-011999-1.50015-8 Кремний. Физическая энциклопедия. Гл. ред. А. М. Прохоров. М.: Советская энциклопедия; 1990. 704 с. Vompe T. N., D’yakonova N., Milyaev I., Prutskov M. Kinetics of s-phase formation in a strain aging hard magnetic Fe-33% Cr-12% Co-2% Cu alloy. Russian Metallurgy (Metally). 2012;(1): 55–57. DOI: https://doi.org/10.1134/s0036029512010168 Генералова К. Н., Ряпосов И. В., Шацов А. А. Порошковые сплавы системы Fe-Cr-Co, термообработанные в области «гребня». Письма о материалах. 2017;7(2): 133–136. DOI: https://doi.org/10.22226/2410-3535-2017-2-133-136 Медь. Физическая энциклопедия. М.: Советская энциклопедия; 1992. 672. International Centre for Diffraction Data (ICDD).Режим доступа: www.icdd.com Козвонин В. А., Шацов А. А., Ряпосов И. В. Поликомпонентные концентрационнонеоднородные сплавы системы Fe–Cr–Co–Si–B повышенной плотности. Вестник ПНИПУ. Машиностроение материаловедение. 2016;18(4): 188–202. DOI: https://doi.10.15595/2224-9877/2016.4.14

González A., Goikolea E., Barrena J. A., Mysyk R. Review on supercapacitors: Technologies and materials. Renew. Sustain. Energy Rev. 2016, 58 1189-1206. Zhong C., Deng Y., Hu W., Qiao J., Zhang L., Zhang J. A review of electrolyte materials and compositions for electrochemical supercapacitors. Chem. Soc. Rev. 2015, 44 (21), 7484-7539. Dahl K., Sando G., Fox D., Sutto T., Owrutsky J. Vibrational spectroscopy and dynamics of small anions in ionic liquid solutions. J. Chem. Phys. 2005, 123 084504. Zhang B., Yuan Z., li X., Ren X., Nian H., Shen Y., Yun Q. Ion-molecule interaction in solutions of lithium tetrafluoroborate in propylene carbonate: An ftir vibrational spectroscopic study. In. J. Electrochem. Sc. 2013, 8 12735-12740. Jow T. R., Xu K., Borodin O., Ue M. Electrolytes for lithium and lithium-ion batteries. Springer: New York, NY, 2014; Vol. 58, p 476. Paschoal V. H., Faria L. F. O., Ribeiro M. C. C. Vibrational spectroscopy of ionic liquids. Chem. Rev. 2017, 117 (10), 7053-7112. Ueno S., Tanimura Y., Ten-no S. Molecular dynamics simulation for infrared spectroscopy with intramolecular forces from electronic properties of on-the-fly quantum chemical calculations. Int. J. Quantum Chem. 2013, 113 (3), 330-335. Xu R. J., Blasiak B., Cho M., Layfield J. P., Londergan C. H. A direct, quantitative connection between molecular dynamics simulations and vibrational probe line shapes. J. Phys. Chem. Lett. 2018, 9 (10), 2560-2567. Choi E., Yethiraj A. Conformational properties of a polymer in an ionic liquid: Computer simulations and integral equation theory of a coarse-grained model. J. Phys. Chem. B 2015, 119 (29), 9091-9097. Li B., Ma K., Wang Y.-L., Turesson M., Woodward C. E., Forsman J. Fused coarse-grained model of aromatic ionic liquids and their behaviour at electrodes. Phys. Chem. Chem. Phys. 2016, 18 (11), 8165-8173. Mehta N. A., Levin D. A. Molecular dynamics electrospray simulations of coarse-grained ethylammonium nitrate (ean) and 1-ethyl-3-methylimidazolium tetrafluoroborate (EMIM-BF4). Aerospace 2018, 5 (1). Son C. Y., McDaniel J. G., Schmidt J. R., Cui Q., Yethiraj A. First-principles united atom force field for the ionic liquid Bmim+BF4–: An alternative to charge scaling. J. Phys. Chem. B 2016, 120 (14), 3560-3568. Tetiana C., Oleg K., Yaroslav K. Microstructure and dynamics of single charged ions in propylene carbonate. Kharkov Univ. Bull. Chem. Ser. 2013, 0 (22), 25-38. Vovchynskyi I. S., Kolesnik Y. V., Filatov Y. I., Kalugin O. N. Molecular modelling on solutions of 1-1′-spirobipirrolidinium tetrafluoroborate in acetonitrile. J. Mol. Liq. 2017, 235 60-67. Sambasivarao S. V., Acevedo O. Development of opls-aa force field parameters for 68 unique ionic liquids. J. Chem. Theory Comput. 2009, 5 (4), 1038-1050. Doherty B., Zhong X., Gathiaka S., Li B., Acevedo O. Revisiting OPLS force field parameters for ionic liquid simulations. J. Chem. Theory Comput. 2017, 13 (12), 6131 6145. Feng G., Huang J., Sumpter B. G., Meunier V., Qiao R. Structure and dynamics of electrical double layers in organic electrolytes. Phys. Chem. Chem. Phys. 2010, 12 (20), 5468-5479. Kanzaki R., Mitsugi T., Fukuda S., Fujii K., Takeuchi M., Soejima Y., Takamuku T., Yamaguchi T., Umebayashi Y., Ishiguro S.-i. Ion–ion interaction in room temperature ionic liquid 1-ethyl-3-methylimidazolium tetrafluoroborate studied by large angle x-ray scattering experiment and molecular dynamics simulations. J. Mol. Liq. 2009, 147 (1), 77-82. Shim Y., Kim H. J. Nanoporous carbon supercapacitors in an ionic liquid: A computer simulation study. ACS Nano 2010, 4 (4), 2345-2355. Shim Y., Jung Y., Kim H. J. Graphene-based supercapacitors: A computer simulation study. J. Phys. Chem. B 2011, 115 (47), 23574-23583. Yang P.-Y., Ju S.-P., Hsieh H.-S., Lin J.-S. The diffusion behavior and capacitance of tetraethylammonium/tetrafluoroborate ions in acetonitrile with different molar concentrations: A molecular dynamics study. RSC Adv. 2017, 7 (87), 55044-55050. Zhang Q.-Y., Xie P., Wang X., Yu X.-W., Shi Z.-Q., Zhao S.-H. Thermodynamic and transport properties of spiro-(1,1')-bipyrrolidinium tetrafluoroborate and acetonitrile mixtures: A molecular dynamics study. Chin. Phys. B 2016, 25 (6), 066102. Liu Z., Huang S., Wang W. A refined force field for molecular simulation of imidazolium-based ionic liquids. J. Phys. Chem. B 2004, 108 (34), 12978-12989. Wu X., Liu Z., Huang S., Wang W. Molecular dynamics simulation of room-temperature ionic liquid mixture of [Bmim][BF4] and acetonitrile by a refined force field. Phys. Chem. Chem. Phys. 2005, 7 (14), 2771-2779. de Andrade J., Böes E. S., Stassen H. Computational study of room temperature molten salts composed by 1-alkyl-3-methylimidazolium cationsforce-field proposal and validation. J. Phys. Chem. B 2002, 106 (51), 13344-13351. Canongia Lopes J. N., Pádua A. A. H. Molecular force field for ionic liquids iii: Imidazolium, pyridinium, and phosphonium cations; chloride, bromide, and dicyanamide anions. J. Phys. Chem. B 2006, 110 (39), 19586-19592. Frisch M. J., Trucks G. W., Schlegel H. B., Scuseria G. E., Robb M. A., Cheeseman J. R., Scalmani G., Barone V., Petersson G. A., Nakatsuji H., Li X., Caricato M., Marenich A. V., Bloino J., Janesko B. G., Gomperts R., Mennucci B., Hratchian H. P., Ortiz J. V., Izmaylov A. F., Sonnenberg J. L., Williams, Ding F., Lipparini F., Egidi F., Goings J., Peng B., Petrone A., Henderson T., Ranasinghe D., Zakrzewski V. G., Gao J., Rega N., Zheng G., Liang W., Hada M., Ehara M., Toyota K., Fukuda R., Hasegawa J., Ishida M., Nakajima T., Honda Y., Kitao O., Nakai H., Vreven T., Throssell K., Montgomery Jr. J. A., Peralta J. E., Ogliaro F., Bearpark M. J., Heyd J. J., Brothers E. N., Kudin K. N., Staroverov V. N., Keith T. A., Kobayashi R., Normand J., Raghavachari K., Rendell A. P., Burant J. C., Iyengar S. S., Tomasi J., Cossi M., Millam J. M., Klene M., Adamo C., Cammi R., Ochterski J. W., Martin R. L., Morokuma K., Farkas O., Foresman J. B., Fox D. J. Gaussian 16 rev. C.01, Wallingford, CT, 2016. Breneman C. M., Wiberg K. B. Determining atom-centered monopoles from molecular electrostatic potentials. The need for high sampling density in formamide conformational analysis. J. Comput. Chem. 1990, 11 (3), 361-373. Cornell W. D., Cieplak P., Bayly C. I., Gould I. R., Merz K. M., Ferguson D. M., Spellmeyer D. C., Fox T., Caldwell J. W., Kollman P. A. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J. Am. Chem. Soc. 1995, 117 (19), 5179-5197. Mayo S. L., Olafson B. D., Goddard W. A. Dreiding: A generic force field for molecular simulations. J. Phys. Chem. 1990, 94 (26), 8897-8909. Schmidt M. W., Baldridge K. K., Boatz J. A., Elbert S. T., Gordon M. S., Jensen J. H., Koseki S., Matsunaga N., Nguyen K. A., Su S., Windus T. L., Dupuis M., Montgomery Jr J. A. General atomic and molecular electronic structure system. J. Comput. Chem. 1993, 14 (11), 1347-1363. Xue H., Twamley B., Shreeve J. n. M. The first 1-alkyl-3-perfluoroalkyl-4,5- dimethyl-1,2,4-triazolium salts. J. Org. Chem. 2004, 69 (4), 1397-1400. Jorgensen W. L., Maxwell D. S., Tirado-Rives J. Development and testing of the opls all-atom force field on conformational energetics and properties of organic liquids. J. Am. Chem. Soc. 1996, 118 (45), 11225-11236. Pádua A. A. H., Costa Gomes M. F., Canongia Lopes J. N. A. Molecular solutes in ionic liquids: A structural perspective. Acc. Chem. Res. 2007, 40 (11), 1087-1096. Pensado A. S., Gomes M. F. C., Lopes J. N. C., Malfreyt P., Pádua A. A. H. Effect of alkyl chain length and hydroxyl group functionalization on the surface properties of imidazolium ionic liquids. Phys. Chem. Chem. Phys. 2011, 13 (30), 13518-13526. Shimizu K., Pensado A., Malfreyt P., Pádua A. A. H., Canongia Lopes J. N. 2d or not 2d: Structural and charge ordering at the solid-liquid interface of the 1 (2 hydroxyethyl)-3-methylimidazolium tetrafluoroborate ionic liquid. Faraday Discuss. 2012, 154 (0), 155-169. Canongia Lopes J. N., Deschamps J., Pádua A. A. H. Modeling ionic liquids using a systematic all-atom force field. J. Phys. Chem. B 2004, 108 (6), 2038-2047. Canongia Lopes J. N., Pádua A. A. H. Molecular force field for ionic liquids composed of triflate or bistriflylimide anions. J. Phys. Chem. B 2004, 108 (43), 16893 16898. Shimizu K., Almantariotis D., Gomes M. F. C., Pádua A. A. H., Canongia Lopes J. N. Molecular force field for ionic liquids v: Hydroxyethylimidazolium, dimethoxy-2- methylimidazolium, and fluoroalkylimidazolium cations and bis(fluorosulfonyl)amide, perfluoroalkanesulfonylamide, and fluoroalkylfluorophosphate anions. J. Phys. Chem. B 2010, 114 (10), 3592-3600. Smith W., Yong C. W., Rodger P. M. DL_POLY: Application to molecular simulation. Mol. Simulat. 2002, 28 (5), 385-471. Lindahl E., Hess B., van der Spoel D. Gromacs 3.0: A package for molecular simulation and trajectory analysis. J. Mol. Model. 2001, 7 (8), 306-317. Pronk S., Páll S., Schulz R., Larsson P., Bjelkmar P., Apostolov R., Shirts M. R., Smith J. C., Kasson P. M., van der Spoel D., Hess B., Lindahl E. Gromacs 4.5: A high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics 2013, 29 (7), 845-854. Van Der Spoel D., Lindahl E., Hess B., Groenhof G., Mark A. E., Berendsen H. J. C. GROMACS: Fast, flexible, and free. J. Comput. Chem. 2005, 26 (16), 1701-1718. Bussi G., Donadio D., Parrinello M. Canonical sampling through velocity rescaling. J. Chem. Phys. 2007, 126 (1), 014101. Berendsen H. J. C., Postma J. P. M., van Gunsteren W. F., DiNola A., Haak J. R. Molecular dynamics with coupling to an external bath. J. Chem. Phys. 1984, 81 (8), 3684-3690. Koverga V. A., Korsun O. M., Kalugin O. N., Marekha B. A., Idrissi A. A new potential model for acetonitrile: Insight into the local structure organization. J. Mol. Liq. 2017, 233 251-261. Agieienko V. N., Kolesnik Y. V., Kalugin O. N. Structure, solvation, and dynamics of Mg2+, Ca2+, Sr2+, and Ba2+ complexes with 3-hydroxyflavone and perchlorate anion in acetonitrile medium: A molecular dynamics simulation study. J. Chem. Phys. 2014, 140 (19), 194501. Kovacs H., Kowalewski J., Maliniak A., Stilbs P. Multinuclear relaxation and nmr self-diffusion study of the molecular dynamics in acetonitrile-chloroform liquid mixtures. J. Phys. Chem. 1989, 93 (2), 962-969. Kunz W., Calmettes P., Bellissent-Funel M. C. Dynamics of liquid acetonitrile at high frequencies. J. Chem. Phys. 1993, 99 (3), 2079-2082. Hurle R. L., Woolf L. A. Self-diffusion in liquid acetonitrile under pressure. J. Chem. Soc. Faraday Trans. 1982, 78 (7), 2233-2238. Hawlicka E., Grabowski R. Solvation of ions in acetonitrile-methanol solutions of sodium iodide. Ber. Bunsenges. Phys. Chern. 1990, 94 (4), 486-489. Holz M., Mao X. a., Seiferling D., Sacco A. Experimental study of dynamic isotope effects in molecular liquids: Detection of translationrotation coupling. J. Chem. Phys. 1996, 104 (2), 669-679. Liang M., Zhang X.-X., Kaintz A., Ernsting N. P., Maroncelli M. Solvation dynamics in a prototypical ionic liquid + dipolar aprotic liquid mixture: 1-butyl-3-methylimidazolium tetrafluoroborate + acetonitrile. J. Phys. Chem. B 2014, 118 (5), 1340-1352. Marcus Y. The properties of solvents. 1998. Marekha B. A., Kalugin O. N., Bria M., Buchner R., Idrissi A. Translational diffusion in mixtures of imidazolium ils with polar aprotic molecular solvents. J. Phys. Chem. B 2014, 118 (20), 5509-5517. Bešter-Rogač M., Stoppa A., Buchner R. Ion association of imidazolium ionic liquids in acetonitrile. J. Phys. Chem. B 2014, 118 (5), 1426-1435.

Follicular lymphoma (FL) is the most common type of indolent lymphoma in the Western world, accounting for approximately 30% of lymphoma cases. FL is known for its recurrent nature, necessitating diverse treatment options. The introduction of rituximab, an anti-CD20 antibody, has greatly improved FL outcomes and paved the way for targeted therapies. In this review, we thoroughly explore the structure, mechanism of action, clinical outcomes, and side effects of currently approved monoclonal antibodies (mAb) for FL. Furthermore, we provide insights into ongoing clinical trials and emerging monoclonal antibodies that hold promise for the future of FL treatment. A comprehensive literature search was conducted using various medical databases, including ASH and ASCO publications, as well as PubMed. The clinicaltrials.gov website was used to compile a list of investigational monoclonal antibodies from ongoing clinical trials. The future of antibody-based therapy for follicular lymphoma shows great promise, with a focus on enhancing antibody efficacy, prioritizing optimized combination therapies to address treatment resistance, and evaluating bispecific antibodies as first-line therapies, all while carefully balancing risks and benefits and sequencing treatments appropriately for better disease management. These directions have the potential to establish antibodies as a central component of follicular lymphoma treatment. Article Details How to Cite MOUSTAFA, Muhamad Alhaj. A Comprehensive Review of Monoclonal Antibodies for the Treatment of Follicular Lymphoma Including Both Approved and Investigational Options. Medical Research Archives, [S.l.], v. 11, n. 11, nov. 2023. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/4745>. Date accessed: 02 dec. 2023. doi: https://doi.org/10.18103/mra.v11i11.4745. ABNT APA BibTeX CBE EndNote - EndNote format (Macintosh & Windows) MLA ProCite - RIS format (Macintosh & Windows) RefWorks Reference Manager - RIS format (Windows only) Turabian Issue Vol 11 No 11 (2023): November Issue, Vol.11, Issue 11 Section Research Articles The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives. References 1. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-2390. doi:10.1182/blood-2016-01-643569 2. Cerhan JR. Epidemiology of Follicular Lymphoma. Hematol Oncol Clin North Am. 2020;34(4):631-646. doi:10.1016/j.hoc.2020.02.001 3. Kaseb H, Ali MA, Koshy NV. Follicular Lymphoma. In: StatPearls. StatPearls Publishing; 2023. Accessed April 8, 2023. http://www.ncbi.nlm.nih.gov/books/NBK538206/ 4. Monga N, Nastoupil L, Garside J, et al. Burden of illness of follicular lymphoma and marginal zone lymphoma. Ann Hematol. 2019;98(1):175-183. doi:10.1007/s00277-018-3501-8 5. Mozas P, Sorigué M, López-Guillermo A. Follicular lymphoma: an update on diagnosis, prognosis, and management. Med Clin (Barc). 2021;157(9):440-448. doi:10.1016/j.medcli.2021.03.041 6. Luminari S, Bellei M, Biasoli I, Federico M. Follicular lymphoma - treatment and prognostic factors. Rev Bras Hematol E Hemoter. 2012;34(1):54-59. doi:10.5581/1516-8484.20120015 7. Illidge T, Chan C. How have outcomes for patients with follicular lymphoma changed with the addition of monoclonal antibodies? Leuk Lymphoma. 2008;49(7):1263-1273. doi:10.1080/10428190802090805 8. Steffanoni S, Ghielmini M, Moccia A. Chemotherapy and treatment algorithms for follicular lymphoma: a look at all options. Expert Rev Anticancer Ther. 2015;15(11):1337-1349. doi:10.1586/14737140.2015.1092386 9. Flowers CR, Leonard JP, Nastoupil LJ. Novel immunotherapy approaches to follicular lymphoma. Hematol Am Soc Hematol Educ Program. 2018;2018(1):194-199. doi:10.1182/asheducation-2018.1.194 10. Marofi F, Rahman HS, Achmad MH, et al. A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions. Front Immunol. 2021;12:681984. doi:10.3389/fimmu.2021.681984 11. Bhatt VR, Armitage JO. Autologous and allogeneic hematopoietic stem cell transplantation in follicular lymphoma. Expert Opin Biol Ther. 2016;16(1):57-66. doi:10.1517/14712598.2016.1096341 12. Lin Z, Liu L, Li Z, Xu B. Bispecific antibodies as monotherapy or in combinations for non-hodgkin B-cell lymphoma: latest updates from the American society of hematology 2022 annual meeting. Exp Hematol Oncol. 2023;12(1):41. doi:10.1186/s40164-023-00404-3 13. Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116(12):2040-2045. doi:10.1182/blood-2010-03-276246 14. van Meerten T, Hagenbeek A. Novel antibodies against follicular non-Hodgkin’s lymphoma. Best Pract Res Clin Haematol. 2011;24(2):231-256. doi:10.1016/j.beha.2011.03.002 15. Marcus R, Davies A, Ando K, et al. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. N Engl J Med. 2017;377(14):1331-1344. doi:10.1056/NEJMoa1614598 16. Johnston PB, Bondly C, Micallef INM. Ibritumomab tiuxetan for non-Hodgkin’s lymphoma. Expert Rev Anticancer Ther. 2006;6(6):861-869. doi:10.1586/14737140.6.6.861 17. Gondran C, Ysebaert L. [Drug approval: Mosunetuzumab - third-line therapy in follicular lymphoma]. Bull Cancer (Paris). 2022;109(11):1105-1106. doi:10.1016/j.bulcan.2022.07.010 18. Allen HC, Sharma P. Histology, Plasma Cells. In: StatPearls. StatPearls Publishing; 2023. Accessed April 11, 2023. http://www.ncbi.nlm.nih.gov/books/NBK556082/ 19. Nelson PN, Reynolds GM, Waldron EE, Ward E, Giannopoulos K, Murray PG. Monoclonal antibodies. Mol Pathol MP. 2000;53(3):111-117. doi:10.1136/mp.53.3.111 20. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256(5517):495-497. doi:10.1038/256495a0 21. Dunn DL. Monoclonal antibodies for diagnosis and treatment. Arch Surg Chic Ill 1960. 1993;128(11):1274-1280. doi:10.1001/archsurg.1993.01420230102016 22. Posner J, Barrington P, Brier T, Datta-Mannan A. Monoclonal Antibodies: Past, Present and Future. Handb Exp Pharmacol. 2019;260:81-141. doi:10.1007/164_2019_323 23. Di Pauli F, Berger T, Reindl M. Monoclonal antibodies in the treatment of multiple sclerosis. Curr Med Chem. 2009;16(36):4858-4868. doi:10.2174/092986709789909585 24. Lloyd EC, Gandhi TN, Petty LA. Monoclonal Antibodies for COVID-19. JAMA. 2021;325(10):1015. doi:10.1001/jama.2021.1225 25. Kaur N, Goyal A, Sindhu RK. Therapeutic Monoclonal Antibodies in Clinical Practice against Cancer. Anticancer Agents Med Chem. 2020;20(16):1895-1907. doi:10.2174/1871520620666200703191653 26. Yamada T. Therapeutic monoclonal antibodies. Keio J Med. 2011;60(2):37-46. doi:10.2302/kjm.60.37 27. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83(2):435-445. 28. Cerny T, Borisch B, Introna M, Johnson P, Rose AL. Mechanism of action of rituximab: Anticancer Drugs. 2002;13:S3-S10. doi:10.1097/00001813-200211002-00002 29. Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin’s lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res. 2001;61(13):5137-5144. 30. Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood. 2000;95(12):3900-3908. 31. Jacobsen E. Follicular lymphoma: 2023 update on diagnosis and management. Am J Hematol. 2022;97(12):1638-1651. doi:10.1002/ajh.26737 32. Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(15):1986-1992. doi:10.1200/JCO.2006.06.4618 33. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106(12):3725-3732. doi:10.1182/blood-2005-01-0016 34. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105(4):1417-1423. doi:10.1182/blood-2004-08-3175 35. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(28):4579-4586. doi:10.1200/JCO.2007.13.5376 36. Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood. 2008;112(13):4824-4831. doi:10.1182/blood-2008-04-153189 37. Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood. 2001;97(1):101-106. doi:10.1182/blood.v97.1.101 38. Ghielmini M, Schmitz SFH, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood. 2004;103(12):4416-4423. doi:10.1182/blood-2003-10-3411 39. Witzig TE, Vukov AM, Habermann TM, et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin’s lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(6):1103-1108. doi:10.1200/JCO.2005.12.052 40. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet Lond Engl. 2011;377(9759):42-51. doi:10.1016/S0140-6736(10)62175-7 41. Martinelli G, Schmitz SFH, Utiger U, et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(29):4480-4484. doi:10.1200/JCO.2010.28.4786 42. Hanif N, Anwer F. Rituximab. In: StatPearls. StatPearls Publishing; 2023. Accessed April 15, 2023. http://www.ncbi.nlm.nih.gov/books/NBK564374/ 43. Freeman CL, Sehn LH. A tale of two antibodies: obinutuzumab versus rituximab. Br J Haematol. 2018;182(1):29-45. doi:10.1111/bjh.15232 44. Goede V, Klein C, Stilgenbauer S. Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin’s lymphomas: a glycoengineered type II CD20 antibody. Oncol Res Treat. 2015;38(4):185-192. doi:10.1159/000381524 45. Mössner E, Brünker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115(22):4393-4402. doi:10.1182/blood-2009-06-225979 46. Niederfellner G, Lammens A, Mundigl O, et al. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood. 2011;118(2):358-367. doi:10.1182/blood-2010-09-305847 47. Suresh T, Lee LX, Joshi J, Barta SK. New antibody approaches to lymphoma therapy. J Hematol OncolJ Hematol Oncol. 2014;7:58. doi:10.1186/s13045-014-0058-4 48. Radford J, Davies A, Cartron G, et al. Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). Blood. 2013;122(7):1137-1143. doi:10.1182/blood-2013-01-481341 49. Amitai I, Gafter-Gvili A, Shargian-Alon L, Raanani P, Gurion R. Obinutuzumab-related adverse events: A systematic review and meta-analysis. Hematol Oncol. 2021;39(2):215-221. doi:10.1002/hon.2828 50. Riley MB. Ibritumomab tiuxetan. Clin J Oncol Nurs. 2003;7(1):110-112. doi:10.1188/03.CJON.109-112 51. Morschhauser F, Radford J, Van Hoof A, et al. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(16):1977-1983. doi:10.1200/JCO.2012.45.6400 52. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 2002;20(15):3262-3269. doi:10.1200/JCO.2002.11.017 53. Rieger K, De Filippi R, Lindén O, et al. 90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 years. Ann Hematol. 2022;101(4):781-788. doi:10.1007/s00277-022-04781-3 54. Alhaj Moustafa M, Borah BJ, Moriarty JP, et al. Yttrium-90 Ibritumomab Tiuxetan is Cost-Effective Compared to Bendamustine + Rituximab in Low-grade Lymphomas. Clin Lymphoma Myeloma Leuk. 2023;23(4):259-265. doi:10.1016/j.clml.2023.01.010 55. Salvaris R, Ong J, Gregory GP. Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell Lymphomas. J Pers Med. 2021;11(5):355. doi:10.3390/jpm11050355 56. Budde LE, Sehn LH, Matasar M, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022;23(8):1055-1065. doi:10.1016/S1470-2045(22)00335-7 57. Jacobson CA, Chavez JC, Sehgal AR, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022;23(1):91-103. doi:10.1016/S1470-2045(21)00591-X 58. Shimabukuro-Vornhagen A, Gödel P, Subklewe M, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6(1):56. doi:10.1186/s40425-018-0343-9 59. Grigor EJM, Fergusson D, Kekre N, et al. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis. Transfus Med Rev. 2019;33(2):98-110. doi:10.1016/j.tmrv.2019.01.005 60. Nitschke L. The role of CD22 and other inhibitory co-receptors in B-cell activation. Curr Opin Immunol. 2005;17(3):290-297. doi:10.1016/j.coi.2005.03.005 61. Tang T, Cheng X, Truong B, Sun L, Yang X, Wang H. Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint. Pharmacol Ther. 2021;219:107709. doi:10.1016/j.pharmthera.2020.107709 62. Dakappagari N, Ho SN, Gascoyne RD, Ranuio J, Weng AP, Tangri S. CD80 (B7.1) is expressed on both malignant B cells and nonmalignant stromal cells in non-Hodgkin lymphoma. Cytometry B Clin Cytom. 2012;82(2):112-119. doi:10.1002/cyto.b.20631 63. Deeks ED. Polatuzumab Vedotin: First Global Approval. Drugs. 2019;79(13):1467-1475. doi:10.1007/s40265-019-01175-0 64. Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10(3):727-742. 65. Rosenbaum CA, Jung SH, Pitcher B, et al. Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance). Br J Haematol. 2019;185(1):53-64. doi:10.1111/bjh.15768 66. Hagenbeek A, Gadeberg O, Johnson P, et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood. 2008;111(12):5486-5495. doi:10.1182/blood-2007-10-117671 67. Czuczman MS, Fayad L, Delwail V, et al. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood. 2012;119(16):3698-3704. doi:10.1182/blood-2011-09-378323 68. Morschhauser F, Leonard JP, Fayad L, et al. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin’s lymphoma: phase I/II results. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(20):3346-3353. doi:10.1200/JCO.2008.19.9117 69. Morschhauser F, Marlton P, Vitolo U, et al. Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. Ann Oncol Off J Eur Soc Med Oncol. 2010;21(9):1870-1876. doi:10.1093/annonc/mdq027 70. Tobinai K, Ogura M, Kobayashi Y, et al. Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma. Cancer Sci. 2011;102(2):432-438. doi:10.1111/j.1349-7006.2010.01809.x 71. Ganjoo KN, de Vos S, Pohlman BL, et al. Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphoma. Leuk Lymphoma. 2015;56(1):42-48. doi:10.3109/10428194.2014.911859 72. Leonard JP, Coleman M, Ketas JC, et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin’s lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 2003;21(16):3051-3059. doi:10.1200/JCO.2003.01.082 73. Advani A, Coiffier B, Czuczman MS, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin’s lymphoma: results of a phase I study. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(12):2085-2093. doi:10.1200/JCO.2009.25.1900 74. Ogura M, Tobinai K, Hatake K, et al. Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy. Cancer Sci. 2010;101(8):1840-1845. doi:10.1111/j.1349-7006.2010.01601.x 75. Kebriaei P, Cutler C, de Lima M, et al. Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. Bone Marrow Transplant. 2018;53(4):449-456. doi:10.1038/s41409-017-0019-y 76. Hamadani M, Radford J, Carlo-Stella C, et al. Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021;137(19):2634-2645. doi:10.1182/blood.2020007512 77. Salles G, Gopal AK, Minnema MC, et al. Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma. Clin Lymphoma Myeloma Leuk. 2019;19(5):275-284. doi:10.1016/j.clml.2018.12.013 78. Fanale M, Assouline S, Kuruvilla J, et al. Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma. Br J Haematol. 2014;164(2):258-265. doi:10.1111/bjh.12630 79. Czuczman MS, Thall A, Witzig TE, et al. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(19):4390-4398. doi:10.1200/JCO.2005.09.018 80. Armand P, Janssens A, Gritti G, et al. Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma. Blood. 2021;137(5):637-645. doi:10.1182/blood.2019004753 81. Press OW, Unger JM, Braziel RM, et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin’s lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24(25):4143-4149. doi:10.1200/JCO.2006.05.8198 82. Leonard JP, Coleman M, Kostakoglu L, et al. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(24):5696-5704. doi:10.1200/JCO.2005.14.803 83. Press OW, Unger JM, Rimsza LM, et al. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(3):314-320. doi:10.1200/JCO.2012.42.4101 84. Nastoupil LJ, Chin CK, Westin JR, et al. Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma. Blood Adv. 2022;6(4):1143-1151. doi:10.1182/bloodadvances.2021006240 85. Leonard JP, Schuster SJ, Emmanouilides C, et al. Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer. 2008;113(10):2714-2723. doi:10.1002/cncr.23890 86. Grant BW, Jung SH, Johnson JL, et al. A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701. Cancer. 2013;119(21):3797-3804. doi:10.1002/cncr.28299 87. Morschhauser F, Flinn IW, Advani R, et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol. 2019;6(5):e254-e265. doi:10.1016/S2352-3026(19)30026-2 88. Diefenbach C, Kahl BS, McMillan A, et al. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study. Lancet Haematol. 2021;8(12):e891-e901. doi:10.1016/S2352-3026(21)00311-2 89. Hutchings M, Mous R, Clausen MR, et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. Lancet Lond Engl. 2021;398(10306):1157-1169. doi:10.1016/S0140-6736(21)00889-8 90. Bannerji R, Arnason JE, Advani RH, et al. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022;9(5):e327-e339. doi:10.1016/S2352-3026(22)00072-2 91. Hutchings M, Morschhauser F, Iacoboni G, et al. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. J Clin Oncol Off J Am Soc Clin Oncol. 2021;39(18):1959-1970. doi:10.1200/JCO.20.03175 92. Subklewe M. BiTEs better than CAR T cells. Blood Adv. 2021;5(2):607-612. doi:10.1182/bloodadvances.2020001792 93. Tapia-Galisteo A, Compte M, Álvarez-Vallina L, Sanz L. When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy. Theranostics. 2023;13(3):1028-1041. doi:10.7150/thno.81494 94. Wu L, Seung E, Xu L, et al. Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation. Nat Cancer. 2020;1(1):86-98. doi:10.1038/s43018-019-0004-z 95. Yao Y, Hu Y, Wang F. Trispecific antibodies for cancer immunotherapy. Immunology. 2023;169(4):389-399. doi:10.1111/imm.13636 96. Fayad L, Offner F, Smith MR, et al. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(5):573-583. doi:10.1200/JCO.2012.42.7211 97. Kolstad A, Illidge T, Bolstad N, et al. Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma. Blood Adv. 2020;4(17):4091-4101. doi:10.1182/bloodadvances.2020002583 98. Palomba ML, Till BG, Park SI, et al. Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Results from a Phase 1b Study. Clin Lymphoma Myeloma Leuk. 2022;22(7):e443-e451. doi:10.1016/j.clml.2021.12.010 99. Morschhauser F, Ghosh N, Lossos IS, et al. Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial. Blood Cancer J. 2021;11(8):147. doi:10.1038/s41408-021-00539-8 100. Czuczman MS, Hess G, Gadeberg OV, et al. Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma. Br J Haematol. 2012;157(4):438-445. doi:10.1111/j.1365-2141.2012.09086.x 101. Westin JR, Chu F, Zhang M, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014;15(1):69-77. doi:10.1016/S1470-2045(13)70551-5 102. Czuczman MS, Leonard JP, Jung S, et al. Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. Ann Oncol Off J Eur Soc Med Oncol. 2012;23(9):2356-2362. doi:10.1093/annonc/mdr620